THURSDAY, May 7, 2020 (HealthDay News) -- Gastrointestinal (GI) symptoms are seen in less than 10 percent of patients with COVID-19, according to a meta-analysis published online May 4 in Gastroenterology.

Shahnaz Sultan, M.D., from the University of Minnesota in Minneapolis, and colleagues performed a systematic literature search to identify studies describing data on GI and liver manifestations of COVID-19. The prevalence of diarrhea, nausea, vomiting, and abdominal pain was analyzed, in addition to liver function test (LFT) abnormalities.

A meta-analysis was performed of 47 studies with 10,890 unique patients; most of the studies involved hospitalized patients. The researchers found that the pooled prevalence estimates for GI symptoms were 7.7, 7.8, and 2.7 percent for diarrhea, nausea/vomiting, and abdominal pain, respectively. The pooled prevalence of elevated liver abnormalities was 15.0 and 15.0 percent for both aspartate transaminase and alanine transaminase, respectively. Diarrhea, nausea/vomiting, and liver abnormalities were more prevalent in countries outside of China, with diarrhea reported in 18.3 percent of patients. Reports of isolated GI symptoms were rare.

Read the full HealthDay story.